Company Interview / Neuren's next leap treating newborns

Jon Pilcher of Neuren Pharmaceuticals (ASX:NEU) shares insights into their latest milestone in treatment development targeting brain injury in newborns. He highlights the massive unmet need, emphasising the devastating impact the condition has on children and their families. Treatment focuses on improving IGF-1 function in the brain to mediate damage and promote better long-term outcomes.

Jon expresses confidence in obtaining orphan drug designation and rare paediatric disease designation, which would facilitate priority review. Neuren plans to discuss their clinical study plans with the FDA and target newborn patients. He notes that setting up clinical trials may be easier due to the patients being in hospitals.

The first approved drug with Acadia Pharmaceuticals generates significant cash flow, enabling funding for further developments. Jon outlines their strategy for the second drug, aiming to treat multiple neurodevelopmental disorders. With substantial cash reserves, Neuren remains in a strong financial position, poised for long-term growth.